2. Cell Cycle/DNA Damage Immunology/Inflammation Apoptosis NF-κB Metabolic Enzyme/Protease
  3. Topoisomerase COX Apoptosis Reactive Oxygen Species
  4. Topo I/COX-2-IN-2

Topo I/COX-2-IN-2 (Compound W10) 是一种有效的 Topo I 和 COX-2 的双靶点抑制剂，IC50 值分别为 0.90 μM 和 2.31 μM。Topo I/COX-2-IN-2 通过线粒体途径诱导癌细胞凋亡（apoptosis）。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Topo I/COX-2-IN-2 Chemical Structure

Topo I/COX-2-IN-2 Chemical Structure

CAS No. : 2841455-91-0

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

Topo I/COX-2-IN-2 相关抗体

Top Publications Citing Use of Products

查看 Topoisomerase 亚型特异性产品:

查看所有亚型
Topoisomerase Topo I Topo II

查看 COX 亚型特异性产品:

查看所有亚型
COX COX-1 COX-2 COX-3

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Topo I/COX-2-IN-2 (Compound W10) is a potent dual-target inhibitor of Topo I and COX-2 with IC50 values of 0.90 μM and 2.31 μM, respectively. Topo I/COX-2-IN-2 induces cancer cell apoptosis through the mitochondrial pathway[1].

IC50 & Target

Topoisomerase I

0.90 μM (IC50)

COX-2

2.31 μM (IC50)

体外研究
(In Vitro)

Topo I/COX-2-IN-2 (Compound W10) (0-30 μM) shows good toxicity against cancer cells[1].
Topo I/COX-2-IN-2 forms an ionic bonding interaction with DA13 of DNA to improve Topo I inhibition[1].
Topo I/COX-2-IN-2 (0-9 μM, 24 h) arrests cell cycle of HT29 and RKO at G1/G0 phase, induces apoptosis in HT29 and RKO cells through the mitochondrial pathway, and inhibits abnormal activation of the NF-κB/IκB pathway. [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Topo I/COX-2-IN-2 相关抗体:

Cell Proliferation Assay[1]

Cell Line: HT29, RKO, HCT116, LoVo and SW480
Concentration: 0-30 μM
Incubation Time: 72 h
Result: Showed good toxicity with IC50 values of 1.48 ± 0.08 μM, 2.06 ± 0.01 μM, 4.89 ± 0.36 μM, 8.42 ± 0.22 μM and 7.36 ± 0.64 μM for HT29, RKO, HCT116, LoVo and SW480 cells, respectively.

Cell Cycle Analysis[1]

Cell Line: HT29 and RKO
Concentration: 2, 4 and 8 μM for HT29; 3, 6 and 9 μM for RKO
Incubation Time: 24 h
Result: Blocked the cell cycle in G1/G0 phase in both HT29 and RKO. In HT29 cells, the arresting activity was not obvious for the ratio of G1/G0 phase in high-concentration treatment group increased from 55.20% to 65.17% slightly, while in RKO cells, the ratio of G1/G0 phase obviously increased from 37.57% to 76.99%.

Apoptosis Analysis[1]

Cell Line: HT29 and RKO
Concentration: 2, 4 and 8 μM for HT29; 3, 6 and 9 μM for RKO
Incubation Time: 24 h
Result: Mainly induced the late apoptosis in HT29 cells and exhibited dual induction of late and early apoptosis in RKO cells.
Induced the production of reactive oxygen species (ROS) burst and significantly reduce the mitochondrial membrane potential.

Western Blot Analysis[1]

Cell Line: HT29 and RKO
Concentration: 2, 4 and 8 μM for HT29; 3, 6 and 9 μM for RKO
Incubation Time: 24 h
Result: Induced increased expression of the pro-apoptotic proteins Bax, cytochrome c and apoptotic effector cleaved caspase 3/9, reduced the expression of the inhibitory factor Bcl-2.
The expressions of phosphorylated NF-κB and IκB were significantly decreased.
体内研究
(In Vivo)

Topo I/COX-2-IN-2 (Compound W10) (15 and 30 mg/kg; i.p.; b.i.d for 2 weeks) inhibits tumor growth and shows obvious necrosis on tumor tissue[1].
Topo I/COX-2-IN-2 has acceptable pharmacokinetic properties for intraperitoneal injection and oral administration[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male BALB/c nude mice weighing 20–25 g, HT29 xenograft model[1]
Dosage: 15 and 30 mg/kg
Administration: Intraperitoneal injection, twice daily for 2 weeks
Result: 30 mg/kg group immediately slowed down the tumor growth rate after administration, and almost completely prevented tumor growth in the later stage, and its tumor growth inhibition (TGI) was 57.86%. 15 mg/kg group showed 40.67% TGI.
Showed obvious necrosis on tumor tissue.
Animal Model: 250–280 g male SD rats[1]
Dosage: 100 mg/kg and 30 mg/kg
Administration: Intragastric administration (100 mg/kg) or intraperitoneal injection (30 mg/kg) (Pharmacokinetics Study)
Result: Pharmacokinetic data of Topo I/COX-2-IN-2 (W10) in vivoa[1]
Comp. Dose
(mg/kg)		 Route T1/2(h) Tmax(h) Cmax
(μg/mL)		 AUC0-t
(μg⋅h/mL)
Topo I/COX-2-IN-2 100 p.o. 8.87 ± 1.92 3.67 ± 0.58 2.00 ± 0.41 24.81 ± 5.76
30 i.p. 4.27 ± 0.22 0.28 ± 0.05 1.60 ± 0.34 5.41 ± 0.20

a Topo I/COX-2-IN-2 was administered to 6 SD rats with different administration methods and doses, and the serum concentration was analyzed. The analysis method is the linear trapezoidal PKsolver 2.0 computer program of the non-compartmental model. All the data are from the above 6 rats, and the data are represented by the mean and standard deviation.
分子量

420.93

Formula

C24H25ClN4O
CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

Topo I/COX-2-IN-2 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Topo I/COX-2-IN-22841455-91-0TopoisomeraseCOXApoptosisReactive Oxygen SpeciesCyclooxygenasecolon cancerHT29RKOBALB/c nude miceInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Topo I/COX-2-IN-2
目录号：
HY-150755
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z